{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:24:47Z","timestamp":1787837087574,"version":"build-2784847793"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:p>EGFR inhibitors have revolutionized the treatment of advanced malignancies by targeting cancer cells specifically. The \u201cPRIDE\u201d complex encompasses a range of cutaneous adverse effects linked to EGFR inhibition therapy, including acneiform eruptions, xerosis, eczema, paronychia, and hair and nail changes. Cutaneous toxicities are among the most reported adverse events in this context. This report presents a case illustrating the dermatological side effects of EGFR inhibition therapy. The case involves a 73-year-old man with colon cancer undergoing (folinic acid, fluorouracil, irinotecan) + cetuximab treatment, presenting with diffuse rash, severe xerosis, bilateral scleral congestion, hyperpigmentation, nail changes, abdomen and toe ulcers, and skin infections.<\/jats:p>","DOI":"10.4103\/jfmpc.jfmpc_1928_24","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T13:01:00Z","timestamp":1748696460000},"page":"2074-2077","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Cutaneous and systemic manifestations of EGFR inhibitor therapy: A case of PRIDE syndrome"],"prefix":"10.4103","volume":"14","author":[{"given":"Fadi Ali","family":"Alghamdi","sequence":"first","affiliation":[{"name":"Department of Dermatology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser Omar","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumayah Dhafer","family":"Alshehri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhar Khalid","family":"Zahrani","sequence":"additional","affiliation":[{"name":"Department of Dermatology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem Khalid","family":"Alhawsawi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema Saeed","family":"Alzaidi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Fuad","family":"Bondagji","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Abdulshakur","family":"Niyazi","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/14712598.2018.1452906","article-title":"Cetuximab for treating non-small cell lung cancer","volume":"18","author":"Mazzarella","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"R2-20250602","first-page":"1462","article-title":"Dermatologic challenges in cancer patients and survivors","volume":"21","author":"Agha","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"R3-20250602","doi-asserted-by":"crossref","first-page":"804212","DOI":"10.3389\/fonc.2022.804212","article-title":"Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"R4-20250602","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"R5-20250602","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4103\/0378-6323.157448","article-title":"Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases","volume":"81","author":"Chanprapaph","year":"2015","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-2133.2006.07452.x","article-title":"The PRIDE (Papulopustules and\/or paronychia, regulatory abnormalities of hair growth, Itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome","volume":"155","author":"Lacouture","year":"2006","journal-title":"Br J Dermatol"},{"key":"R7-20250602","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4103\/0019-5154.131398","article-title":"Dermatological side effects of epidermal growth factor receptor inhibitors: 'PRIDE'complex","volume":"59","author":"Madke","year":"2014","journal-title":"Indian J Dermatol"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0739-5930(09)79406-1","article-title":"Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer","author":"Pearson","year":"2010","journal-title":"Yearbook of Gastroenterology: Elsevier BV"},{"issue":"(Suppl 1)","key":"R9-20250602","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3747\/co.v17is1.615","article-title":"Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer","volume":"17","author":"Fakih","year":"2010","journal-title":"Curr Oncol"},{"key":"R10-20250602","doi-asserted-by":"crossref","first-page":"199ra11","DOI":"10.1126\/scitranslmed.3005886","article-title":"Epidermal EGFR controls cutaneous host defense and prevents inflammation","volume":"5","author":"Lichtenberger","year":"2013","journal-title":"Sci Transl Med"},{"issue":"(Suppl 1)","key":"R11-20250602","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"R12-20250602","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","article-title":"Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R13-20250602","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2006.09.013","article-title":"Nail toxicity associated with epidermal growth factor receptor inhibitor therapy","volume":"56","author":"Fox","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R14-20250602","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1634\/theoncologist.2008-0149","article-title":"Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy","volume":"13","author":"Jatoi","year":"2008","journal-title":"Oncologist"},{"key":"R15-20250602","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.clcc.2017.12.004","article-title":"Dermatologic toxicity occurring during anti-egfr monoclonal inhibitor therapy in patients with metastatic colorectal cancer: A systematic review","volume":"17","author":"Lacouture","year":"2018","journal-title":"Clin Colorectal Cancer"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1928_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:15:21Z","timestamp":1787836521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1928_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1928_24","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2024-11-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}